CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Kyowa Kirin, Kura to Present First Ziftomenib-FLT3 Inhibitor Combination Data at ASH 2026

By Public Technologies
  • Kyowa Kirin and Kura Oncology will present first ziftomenib-FLT3 inhibitor clinical results at ASH, December 12-15, 2026, in New Orleans.
  • Studies assess ziftomenib with quizartinib in newly diagnosed AML or gilteritinib in relapsed or refractory disease, targeting NPM1/FLT3 co-mutations.
  • Longer-term frontline results for ziftomenib with venetoclax and azacitidine support the ongoing Phase 3 KOMET-017 registrational study.
  • An exploratory analysis supports further investigation of ziftomenib in molecularly defined AML populations beyond NPM1-mutated and KMT2A-rearranged disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyowa Kirin Co. Ltd. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.